SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

velzatinib

GSK·GSK plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
Estimated at least 5+ years away, given that both Phase 3 trials have primary completion dates around 2030-2032 and no regulatory submission has been announced.
Why 3/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. Both Phase 3 trials have estimated primary completion dates around 2030-2032, and velzatinib is a single asset within GSK's large diversified pipeline, so its impact on GSK's share price is limited.
Actionable Insight NEUTRAL

The next meaningful catalyst for velzatinib is continued enrollment and data updates from the two Phase 3 trials (StrateGIST Frontline and StrateGIST 3), but neither has a near-term readout given estimated primary completion dates around 2030-2032. Investors should watch for any interim analysis announcements or potential accelerated regulatory filing pathway discussions, though none are currently scheduled. For GSK, velzatinib is one of many pipeline assets and not a near-term binary driver for the stock.

Price Chart

Loading chart...

Executive Summary

Velzatinib (IDRX-42/GSK6042981) is an investigational oral KIT inhibitor for gastrointestinal stromal tumors (GIST) being developed by GSK plc, which acquired the asset through its $1B+ purchase of IDRx in January 2025. At ASCO 2026, Phase 1/1b data showed a 61% response rate in first-line and 35-38% in second-line GIST patients, with broad activity across KIT mutations. Two Phase 3 trials are underway: StrateGIST Frontline (velzatinib vs imatinib in first-line) and StrateGIST 3 (velzatinib vs sunitinib in second-line), but both have estimated durations of approximately 5 years with no near-term binary catalyst. The drug has FDA Fast Track and Orphan Drug designations. For GSK, a large diversified pharma, velzatinib is a promising but distant pipeline asset with limited near-term share price impact.

How It Works

Velzatinib is a pill that blocks a protein called KIT, which acts like an 'on switch' for cancer cell growth in gastrointestinal stromal tumors (GIST). Unlike older drugs that stop working when the KIT protein mutates, velzatinib is designed to hit many different versions of the mutated KIT protein at once, potentially keeping the cancer under control for longer.

Trial Status

Two Phase 3 trials are ongoing. StrateGIST Frontline (NCT07585266) comparing velzatinib vs imatinib in first-line GIST began enrollment in July 2026 and has expanded to 93 sites. StrateGIST 3 (NCT07218926) comparing velzatinib vs sunitinib in second-line GIST after imatinib opened recruitment in December 2025 with an estimated 5-year duration. Phase 1/1b StrateGIST 1 data was presented at ASCO 2026 showing a 61% response rate in first-line (n=18) and 35-38% in second-line (n=46-49) patients.

The Two-Sided Case

▲ Bull Case4
Velzatinib showed a 61% response rate in first-line GIST and 35-38% in second-line at ASCO 2026, with greater than 99% reductions in circulating tumor DNA across KIT mutations, suggesting broad and potent activity.
The drug is designed as a single-agent therapy targeting the full spectrum of primary and secondary KIT mutations, potentially offering a simpler treatment paradigm versus combination approaches like bezuclastinib plus sunitinib.
FDA has granted both Fast Track and Orphan Drug designations, which could accelerate development and provide market exclusivity upon approval.
GSK paid $1B upfront (up to $1.15B total) to acquire IDRx for velzatinib, signaling strong internal conviction, and accelerated the Phase 3 frontline trial start based on early data.
▼ Bear Case4
Both Phase 3 trials (StrateGIST Frontline and StrateGIST 3) have estimated durations of approximately 5 years, with primary completion dates around 2030-2032, meaning no near-term binary catalyst and a long wait for pivotal data.
Cogent Biosciences' bezuclastinib is a direct competitor that also presented compelling Phase 3 PEAK data at ASCO 2026, potentially capturing market share in second-line GIST before velzatinib can reach the market.
As a single asset within GSK's massive pipeline (166+ active trials), velzatinib's success or failure has limited impact on GSK's overall stock price, reducing its appeal as a catalyst-driven investment.
The Phase 1/1b data is still early (n=18 for first-line, n=46-49 for second-line), and response rates may not translate to the overall survival or progression-free survival endpoints required for regulatory approval.

Upcoming Catalysts

  • Continued enrollment updates from StrateGIST Frontline and StrateGIST 3 Phase 3 trials
  • Potential interim analysis announcements (none currently scheduled)
  • Future medical conference data presentations (e.g., ASCO GI, ESMO)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 15

Hover a chip for the title
1 gsk.com2 gsk.com3 fiercebiotech.com4 ascopubs.org5 ascopubs.org6 ascopubs.org7 gsk-studyregister.com8 gsk-studyregister.com9 clinicaltrials.gov10 clinicaltrials.gov11 adisinsight.springer.com12 targetedonc.com13 trial.medpath.com14 bioreview.com15 gsk.com